Stay updated on KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page's revision metadata changed from v3.3.3 to v3.3.4; there are no changes to study details or visible content.
    Difference
    0.1%
    Check dated 2026-01-14T01:12:43.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    A consolidated Locations section now lists North Carolina and South Carolina locations, replacing the prior North Carolina Locations and South Carolina Locations subsections. The footer now shows Revision: v3.3.3 and the HHS Vulnerability Disclosure link has been removed.
    Difference
    0.3%
    Check dated 2025-12-23T09:46:52.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Footer revision from v3.3.1 to v3.3.2; no changes to study details or trial data.
    Difference
    0.1%
    Check dated 2025-12-01T17:56:32.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Page revision updated from v3.2.0 to v3.3.1. No changes were made to the study details or user-facing content.
    Difference
    0.1%
    Check dated 2025-11-24T15:02:58.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The government funding/operating status notice has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T07:17:39.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    Results have been posted for the study, including primary and secondary outcomes (PFS, response rate, and overall survival) and related time frames. Updated study dates reflect the start date, primary completion date, and study completion date.
    Difference
    0.4%
    Check dated 2025-11-03T01:30:12.000Z thumbnail image

Stay in the know with updates to KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.